Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 8, 1997, Pages 2414-2422

  Lacroix, Andre ^a,c   Tremblay, Johanne ^a,c   Touyz, Rhian M ^b,c   Deng, Li Yuan ^b,c   Lariviere, Richard ^b,c   Cusson, Jean R ^a,c   Schiffrin, Ernesto L ^a,b,c   Hamet, Pavel ^a,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANDROGEN; ANGIOTENSIN; ARGIPRESSIN; ARGIPRESSIN[1 (3,3 CYCLOPENTAMETHYLENE 3 MERCAPTOPROPIONIC ACID) 2 (O METHYLTYROSINE)]; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DESMOPRESSIN ACETATE; DEXAMETHASONE; ENDOTHELIN 1; FLUDROCORTISONE; FURA 2 ACETOXYMETHYL ESTER; GLUCAGON; GONADORELIN; GROWTH HORMONE RELEASING FACTOR[1-29]; HYDROCORTISONE; ISOPRENALINE; MIDODRINE; NORADRENALIN; POLOXAMER; PROTIRELIN; RELEFACT; RENIN; SARAFOTOXIN S6C; TETRACOSACTIDE; VASOPRESSIN; VASOPRESSIN V1 RECEPTOR;

ADRENAL HYPERPLASIA; ADRENALECTOMY; ADULT; ALDOSTERONE BLOOD LEVEL; ANDROGEN BLOOD LEVEL; ARTICLE; BLOOD VESSEL REACTIVITY; CASE REPORT; CLINICAL PROTOCOL; CONTROLLED STUDY; CUSHING SYNDROME; DEXAMETHASONE SUPPRESSION TEST; FEMALE; HUMAN; HUMAN CELL; HYDROCORTISONE BLOOD LEVEL; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; STEROIDOGENESIS; SUBCUTANEOUS DRUG ADMINISTRATION; VASOCONSTRICTION;

ADRENAL GLANDS; ADRENALECTOMY; ADRENOCORTICOTROPIC HORMONE; ADULT; ARGININE VASOPRESSIN; BLOOD PRESSURE; CALCIUM; CORTICOTROPIN-RELEASING HORMONE; CUSHING SYNDROME; DEXAMETHASONE; FEMALE; HUMANS; HYDROCORTISONE; HYPERPLASIA; HYPOTENSION, ORTHOSTATIC; KINETICS; POSTURE; RECEPTORS, VASOPRESSIN;

POMACANTHUS MACULOSUS;

EID: 0030833690     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.8.2414     Document Type: Article

References (45)

1. Nieman L, Cutler Jr GB. 1995 Cushing's syndrome. In: De Groot LJ, ed. Endocrinology. Philadelphia: Saunders; 1741-1770.
2. Lieberman SA, Eccleshall TR, Feldman D. 1994 ACTH-independent massive bilateral adrenal disease (AIMBAD): a subtype of Cushing's syndrome with major diagnostic and therapeutic implications. Eur J Endocrinol. 131:67-73.
3. Stratakis CA, Carney CA, Lin JP, et al. 1996 Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromodome 2. J Clin Invest. 97:699-705.
4. Weinstein LS, Shenker A, Gejman PV, et al. 1991 Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 325:1688-1695.
5. Lacroix A, Boité E, Tremblay J, et al. 1992 Gastric inhibitory polypeptide-dependent Cortisol hypersecretion: a new cause of Cushing's syndrome. N Engl J Med. 327:974-980.
6. Reznik Y, Allali Zerah V, Chayvialle JA, et al. 1992 Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med. 327:981-986.
7. Archambeaud-Mouveroux F, Comas JM, Teissier MP, et al. 1996 Food-dependent Cushing's syndrome associated with the Carney complex. Proc of the 78th Annual Meeting of The International Endocrine Society, San Francisco, CA, 1996, p 899.
8. Hamet P, Larochelle P, Franks DJ, Cartier P, Boité E. 1987 Cushing syndrome with food-dependent periodic hormonogenesis. Clin Invest Med. 10:530-533.
9. De Herder WW, Hofland LJ, Usdin TB, et al. 1996 Food-dependent Cushing's syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. J Clin Endocrinol Metab. 81:3168-3172.
10. Bichet DG, Kortas C, Mettauer B, et al. 1986 Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int. 29:1118-1196.
11. Cusson JR, Tremblay J, Larochelle P, Schiffrin EL, Gutkowska J, Hamet P. 1994 Clinical relationships of cyclic GMP. Adv Pharmacol. 26:305-319.
12. Schiffrin EL, Thibault G. 1991 Plasma endothelin in human essential hypertension. Am J Hypertens. 4:303-308.
13. Touyz RM, Larivière R, Schiffrin EL. 1995 Endothelin receptor subtypes in mesenteric vascular smooth muscle cells of SHR. Can J Physiol Pharmacol. 73:1262-1273.
14. Larivière R, Schiffrin EL. 1987. Effect of monovalent and divalent cations and of guanine nucleotides on binding of vasopressin to the rat mesenteric vasculature. Can J Physiol Pharmacol. 65:1171-1181.
15. Perraudin V, Delarue C, De Keyzer Y, et al. 1995 Vasopressin-responsive adrenocortical tumor in a mild Cushing's syndrome: in vivo and in vitro studies. J Clin Endocrinol Metab. 80:2661-2667.
16. Schiffrin EL, Deng L, Larochelle P. 1992 Morpohology of resistance arteries and comparison of effects of vasoconstrictors in mild essential hypertensive patients. Clin Invest Med. 16:177-189.
17. Van Wijk PA, Rijnberk A, Croughs RJM, Wolfswinkel J, Selman PJ, Mol JA. 1994 Responsiveness to ACTH-releasing hormone and vasopressin in canine Cushing's syndrome. Eur J Endocrinol. 130:410-416.
18. Horiba N, Suda T, Aioba M, et al. 1995 Lysine vasopressin stimulation of cortisol secretion in patients with adrenocorticotropin-independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab. 80:2336-2341.
19. 1a vasopressin receptors. J Biol Chem. 269:3304-3310.
20. Birnbaumer M, Seibold A, Gilbert S, et al. 1992 Molecular cloning of the receptor for human antidiuretic hormone. Nature. 357:333-335.
21. De Keyzer Y, Auzan C, Lenne F, et al. 1994 Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett. 356:215-220.
22. Payet N, Deziel Y, Lehoux JG. 1984 Vasopressin: a potent growth factor in adrenal glomerulosa cells in culture. J Steroid Biochem. 20:449-454.
23. Brooks VL, Blakemore LJ. 1989 Vasopressin: a regulator of adrenal glucocorticoid production? Am J Physiol. 256:E566-E572.
24. Larcher A, Delarue C, Idres S, et al. 1989 Identification of vasotocin-like immunoreactivity in chromaffin cells of the frog adrenal gland: effect of vasotocin on corticosteroid secretion. Endocrinology. 125:2691-2700.
25. Bird IM, Nicol M, Williams BC, Walker SW. 1990 Vasopressin stimulates cortisol secretion and phosphoinositide catabolism in cultured bovine adrenal fasciculata/reticularis cells. J Mol Endocrinol. 5:109-116.
26. Adashi EY, Hsueh JW. 1981 Direct inhibition of testicular androgen biosynthesis by arginin-vasopressin: mediation through pressor-selective testicular recognition sites. Endocrinology 109: 1793-1795.
27. 1 receptors. J Clin Endocrinol Metab. 76:1522-1528.
28. Guillon G, Trueba M, Joubert D, et al. 1995 Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. Endocrinology. 136:1285-1295.
29. Guillon G, Balestre MN, Roberts JM, Botari SP. 1987 Oxytocin and vasopressin: distinct receptors in myometrium. J Clin Endocrinol Metab. 64:1129-1135.
30. Parma J, Duprey L, Van Sande J, et al. 1993 Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature. 365:649-651.
31. Shenker A, Lane L, Kosugi S, Merendino Jr JJ, Minegiski T, Cutler Jr GB. 1993 A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature. 365:652-654.
32. Hinshaw HT, Ney RL. 1974 Abnormal hormonal control in the neoplastic adrenal cortex. In: McKerns KVV, ed. Hormones and cancer. New York: Academic Press; 309-327.
33. Lacroix A, Boité É, Tremblay J, Hamet P. 1993 Syndrome de Cushing induit par le GIP: expression clinique d'un récepteur ectopique. Médecine Sciences. 9:706-715.
34. De Keyzer Y, Lenne F, Auzan C, et al. 1996 The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. J Clin Invest. 97:1311-1318.
35. Malerbi DA, Mendonça BB, Liberman B, et al. 1993. The desmopressin stimulation test in the differential diagnosis of Cushing's syndrome. Clin Endocrinol. 38:463-472.
36. Zerbe EL, Henry DP, Robertson GL. 1983 Vasopressin response to orthostatic hypotension; etiologic and clinical implications. Am J Med. 74:265-271.
37. Berghorn KA, Knapp LT, Hoffman GE, Sherman TG. 1995 Induction of glucocorticoid receptor expression in hypothalamic magnocellular vasopressin neurons during chronic hypoosmolality. Endocrinology. 136:804-807.
38. Imai T, Hirata Y, Eguchi S., et al. 1992 Concomitant expression of receptor subtype and isopeptide of endothelin by human adrenal gland. Biochem Biophys Res Commun. 182:1115-1121.
39. Hinson JP, Vinson GP, Kapas S, Teja R. 1991 The role of endothelin in the control of adrenocortical function: stimulation of endothelin release by ACTH and the effects of endothelin-1 and endothelin-3 on steroidogenesis in rat and human adrenocortical cells. J Endocrinol. 128:275-280.
40. Liard J-F. 1994 L-NAME antagonizes vasopressin V-2 induced vasodilatation in dogs. Am J Physiol. 266:H99-H106.
41. Kim P, Katusic ZS, Vanhoutte PM. 1988 Endothelium-dependent responses to arginine-vasopressin. In: Cowley AW, Liard J-F, Ausiello DA, eds. Vasopressin: cellular and integrative functions. New York: Raven Press Ltd; 455-459.
42. Yoshizawa T, Shinmi O, Giaid A, et al. 1990 Endothelin: a novel peptide in the posterior pituitary system. Science. 247:462-464.
43. Kaufman H, Oribe E, Oliver JA. 1991 Plasma endothelin during upright tilt: relevance for orthostatic hypotension?. Lancet. 338:1542-1545.
44. Yamamura Y, Ogawa H, Chihara T, et al. 1991 OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 252:572-574.
45. 1a receptors. J Clin Invest. 92:224-231.